________________________________________________________________________________________________________________________________

(C) ZAHW 2016 Sonia de Andrade gelatin SEMPrintable matrices for bioprinting applications

- Short Communication by Markus Rimann

February 2017: Gelatine-derivatives are widely used in bioprinting due to their cell-compatibility. However this criterion is by far not sufficient for industrial applications. Markus Rimann  develops bioprinting technologies for cell cultivation in tissue-like environments for drug and substance testing at Zürcher Hochschule für Angewandte Wissenschaften (ZHAW). He collaborates with industry partners such as regenHU SA (former Delta Robotics, now part of CPA Group SA) at Villaz-Saint-Pierre (CH), or the Novartis Institutes for BioMedical Research at Basel (CH).

In the short communication he provides a brief sketch of issues and current solutions following discussions of his group’s work during the January meeting of EPFL and Swiss scienceindustries (former Swiss Society of Chemical Industries) at Saas Fee.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Read Now - Please select your license (Prices incl. 7% VAT)
2 pages free of advertisements

Article free of advertisement
- Includes experimental data within the regenHu collaboration

Full Company License enquire here

Back to section

 

Related Editorial Articles

B2Bioworld offers you background information

Triggering Regenerative Functions with Transplanted Cells and Small Molecules
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis

Preparing for another Level of Innovation
Mark Fishman, former President of the Novartis Institutes for BioMedical Research and Member of the Executive Committee of Novartis, comments his company’s strategy in the stem cells field including technology acquisitions in the field

European and U.S. Codes of Conduct for Development of Robotics and Artificial Intelligence

The Laboratory Furniture Market
Assessment and Outlook by Tobias Thiele, Managing Director of Köttermann Group

Instrument Standards: We need the users, and users have to adopt it
A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing by Oscar-Werner Reif, Member of Board Sartorius Stedim Biotech S.A.

Handling Suppliers of Mass Spectrometers Delicately
Michael Myers, International Centre for Genetic Engineering and Biotechnology, Trieste (IT) tells how he avoids getting trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats

Automated Laboratory Instruments: Everyone Re-invents the Wheel
Michael Collasius, Vice President Automated Systems Qiagen NV, on industry-wide standards for laboratory instruments

Laboratory Environments and Science
Irene Coin talks about working in different labs at Universities of Padua (Italy) or Leipzig (Germany), at Arizona’s Biodesign Institute or the Californian Salk Institute for Biological Studies

I want to do what I want to do
Autophagy Researcher Thomas Wollert about Living for Science

Systems Biology Applied
Systems Biology needs sound theoretical concepts. Massive technology set-ups won’t resolve alone the puzzle. A conversation with Prof. Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine on key concepts of systems theory. How they can mislead or fruitfully inform experimental systems biology

Swiss Industrial Biotechnology Network